Background: Nausea and vomiting in pregnancy affects up to 80% of pregnant women and may progress to hyperemesis gravidarum, leading to maternal morbidity and adverse pregnancy outcomes. Despite numerous pharmacological and non-pharmacological options, the comparative efficacy and safety of these interventions remain unclear. Methods: We conducted a systematic review and network meta-analysis of randomized controlled trials assessing pharmacological and non-pharmacological interventions for nausea and vomiting in pregnancy. The databases searched included CENTRAL, PubMed, and EMBASE (up to 28 May 2024). Eligible trials compared interventions with a placebo in pregnant women with nausea and vomiting in pregnancy. The primary outcomes were symptom severity, assessed using validated tools. Safety outcomes included adverse effects. Data were pooled using frequentist pairwise and network meta-analyses. The risk of bias was assessed using the RoB2 tool, and the certainty of evidence was evaluated using the CINeMA framework. Results: Of 9844 records screened, 24 randomized controlled trials (3017 participants) met the inclusion criteria, encompassing 16 intervention categories. Network analysis ranked quince, vitamin B6 with pomegranate and mint, acupressure P6, dimenhydrinate, and acupuncture combined with doxylamine–pyridoxine as the most effective interventions for reducing symptoms of nausea and vomiting in pregnancy, with considerable uncertainty and low-to-moderate quality of evidence. Reporting of adverse events was limited. Risk of bias was low to moderate. Discussion: Most interventions demonstrated significant benefit over a placebo. However, high heterogeneity and sparse reporting of adverse effects warrant caution when translating these results into clinical practice. Conclusions: This study indicates that both pharmacological (vitamin B6, metoclopramide, dimenhydrinate) and non-pharmacological (ginger, quince, acupressure, acupuncture) interventions might be effective in reducing symptoms of nausea and vomiting in pregnancy.
The objective of this study is to evaluate the systemic immune-inflammation index (SII) and systemic inflammation response index (SIRI) in relation to lymph node metastasis, lymphovascular space invasion (LVSI), tumor size, stromal invasion depth, and p16/p53 status in vulvar squamous cell carcinoma. This retrospective single-center cohort study included 92 patients treated between January 2017 and March 2026. SII and SIRI were calculated from routine complete blood counts. Associations were assessed using non-parametric tests and multivariable logistic regression. Receiver operating characteristic analysis evaluated discrimination, expressed as the area under the curve (AUC), with paired DeLong comparison of the two indices. Incremental predictive value was assessed by nested logistic regression, with internal validation using 2000 bootstrap resamples. Both indices were higher in patients with lymph node metastasis and LVSI and correlated positively with tumor size, but not with stromal invasion depth or p16/p53 status. Discrimination was moderate and similar for lymph node metastasis (AUC, 0.670 vs 0.653; paired DeLong, p = 0.679) and for LVSI (0.733 vs 0.732; p = 0.964). In the cutoff-based multivariable model, elevated SIRI remained independently associated with lymph node metastasis (adjusted odds ratio, 4.30; 95% confidence interval, 1.51–12.27; p = 0.006), whereas elevated SII did not. Adding continuous SIRI to a clinicopathological base model improved neither fit (p = 0.159) nor discrimination (AUC difference, 0.013; p = 0.716). SII and SIRI were associated with adverse pathological features, but their discriminatory performance did not differ significantly, and SIRI provided no significant incremental predictive value beyond the clinicopathological base model. These indices should be considered exploratory adjunctive biomarkers requiring external validation. Graphical Abstract
Background: Prognosis in vulvar squamous cell carcinoma (VSCC) is strongly influenced by lymph node involvement and adverse clinicopathological features. Systemic inflammatory indices derived from blood counts may reflect tumor–host interactions associated with adverse pathological phenotypes. Objective: To assess associations of preoperative neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) with nodal metastasis, lymphovascular space invasion (LVSI), and tumor size. Methods: This retrospective single-center study included 93 surgically treated patients between March 2017 and February 2026. Results: NLR was associated with nodal metastasis (unadjusted p = 0.015; false discovery rate [FDR]-adjusted q = 0.047) and LVSI (unadjusted p < 0.001; FDR-adjusted q = 0.006). NLR showed modest discrimination for nodal metastasis (area under the receiver operating characteristic curve [AUC] = 0.647). For LVSI, NLR had the highest AUC among the evaluated markers (AUC = 0.789; 95% confidence interval [CI]: 0.683–0.894), but 16 cases were positive and the positive predictive value (PPV) was low (0.378). Nominal MLR findings for LVSI and large tumor size did not remain significant after FDR correction (both q = 0.308), while PLR showed no consistent associations. Elevated NLR was associated with nodal metastasis in univariable analysis (odds ratio [OR] = 3.291; p = 0.012) but not in multivariable models including LVSI (adjusted OR = 1.296; p = 0.654) or excluding LVSI (adjusted OR = 1.823; p = 0.261). Conclusions: NLR was associated with adverse pathological features but was not independently associated with nodal metastasis and should not be used as a standalone predictive or clinical decision-making tool.